Gilead's Truvada faces a tough audience for HIV-prevention use

About a year and a half ago, the FDA approved the Gilead Sciences ($GILD) pill Truvada to prevent HIV infection in high-risk patients. But demand has been slow to build, The New York Times reports. Some doctors are skeptical, and some men fear the stigma of using an HIV-prevention pill. Plus, younger generations of gay men aren't as fearful of HIV as older men are, the Times says. Report (sub. req.)

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.